Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23487048 | 1.00 | ALDH1A1 (0.45) | ALDH1A1HSD17B10MDM2L3MBTL1GAA | |
| SCHEMBL18458286 | 0.91 | MDM2 (0.41) | ALDH1A1HSD17B10MDM2L3MBTL1GAA | |
| SCHEMBL16171239 | 0.91 | MDM2 (0.41) | ALDH1A1HSD17B10MDM2L3MBTL1GAA | |
| SCHEMBL681668 | 0.91 | — | — | |
| SCHEMBL2600363 | 0.91 | MDM2 (0.41) | ALDH1A1HSD17B10MDM2L3MBTL1GAA | |
| Hydrochloric Acid SCHEMBL15847512 | 0.88 | — | — | |
| SCHEMBL18684792 | 0.81 | GAA (0.43) | ALDH1A1HSD17B10MDM2L3MBTL1GAA | |
| SCHEMBL104716 | 0.81 | — | — | |
| SCHEMBL104342 | 0.81 | — | — | |
| SCHEMBL10259802 | 0.80 | EPHX1 (0.41) | ALDH1A1MDM2L3MBTL1GAAIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | DCX, NES, MCL1 | ALDH1A1 102/4885HSD17B10 783/4885MDM2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.